Perceive Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.perceivebio.com
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Perceive Biotherapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT06087458
- Locations
- 🇦🇺
Cerulea Clinical Trials, East Melbourne, Victoria, Australia
🇮🇱Rambam Medical Center, Haifa, Israel
🇦🇺Sydney Retina Clinic and Day Surgery, Sydney, New South Wales, Australia
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Phase 1
Active, not recruiting
- Conditions
- Age-related Macular DegenerationGeographic Atrophy
- Interventions
- Biological: VOY-101
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Perceive Biotherapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05380492
- Locations
- 🇺🇸
Retina Consultants of Texas, Bellaire, Texas, United States
🇺🇸Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
© Copyright 2025. All Rights Reserved by MedPath